MFDS designates renal cell carcinoma therapy ‘cabozantinib’ as orphan drug

‘Cabozantinib,’ a progressive renal cell carcinoma treatment, will be designated as orphan drug.

The Ministry of Food and Drug Safety(MFDS) will make a pre-announcement of the ‘Partial Amendment to the Regulation for Designation of Orphan Drugs’ on the 6^th, and said it will additionally designate cabozantinib as ‘orphan drug’ and udenafil as ‘orphan drug on development stage.’

The MFDS’ plan ...